Scientific article
English

Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination

Published in

Vaccine, vol. 26, no. 26, p. 3252-3260

Publication date

2008

Abstract

Chemokine receptors are promising targets for enhancing T-cell immunity and anti-cancer therapy. CCL5 is a potential adjuvant for DNA vaccination. We postulated that CCR5 superagonists could be even more effective. A CCR5 superagonist derived from natural CCL5 by directed in vitro evolution, namely 1P7, is used as a DNA vaccine adjuvant and expressed as fused chemokine-Ig (1P7-Ig). We show that OVA+1P7-Ig DNA co-inoculation induced higher frequencies of OVA-specific CD8 lymphocytes than OVA+CCL5-Ig or controls and gave an even better protection against tumor growth in a CCR5-dependant manner. Our results indicate that CCR5-superagonists may provide potent adjuvants for vaccines.

Keywords

  • Adjuvants, Immunologic
  • Animals
  • CD8-Positive T-Lymphocytes/immunology
  • Cancer Vaccines/immunology
  • Chemokine CCL5/genetics/immunology/pharmacology
  • Female
  • Mice
  • Mice, Inbred C57BL
  • Ovalbumin/immunology
  • Receptors, CCR5/agonists
  • Vaccination/methods
  • Vaccines, DNA/immunology

Citation (ISO format)

DORGHAM, Karim et al. Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination. In: Vaccine, 2008, vol. 26, n° 26, p. 3252–3260. doi: 10.1016/j.vaccine.2008.04.003

Main files (1)

Article (Accepted version)

Identifiers

Journal ISSN

0264-410X
598views
5downloads

Technical informations

Creation

18/06/2009 12:15:00

First validation

18/06/2009 12:15:00

Update

08/01/2025 10:35:12

Status update

08/01/2025 10:35:12

Last indexation

08/01/2025 10:36:39
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated